Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Following approval from the European Commission, PFE's Hympavzi becomes the first hemophilia medicine in the European Union ...
GlobalData on MSN2d
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
HYMPAVZI is the first anti-TFPI approved in the EU for this indication and the first therapy to be administered through a pre ...
PMLiVE11h
Pfizer’s Hympavzi receives EC approval to treat haemophilia A and B patients
Pfizer’s Hympavzi (marstacimab) has been approved by the European Commission (EC) to treat haemophilia A or B in adult and ...
The Pharma Letter2d
EC approval for Pfizer’s Hympavzi
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. The ...
Pfizer's HYMPAVZI Approved In EU For Treatment Of Severe Hemophilia A Or B Without Inhibitors
Drug major Pfizer Inc. (PFE) announced Wednesday that the European Commission or EC has granted marketing authorization for HYMPAVZI ...
Daily2d
Pfizer's HYMPAVZI gets European Commission Approval to Treat Severe Hemophilia A and B
Delhi: Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab) ...
Outsourcing-pharma2d
Pfizer’s HYMPAVZI for Hemophilia A or B receives EU approval
The European Commission has approved Pfizer’s treatment for adults and adolescents with severe hemophilia A or B.
Armed robbery in Revesby2d
EU Greenlights Pfizer's HYMPAVZI for Severe Hemophilia
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the ...
Pfizer announces EC approval for Hympavzi
Pfizer (PFE) announced that the European Commission, or EC, has granted marketing authorization for Hympavzi for the routine prophylaxis of ...
Pfizer Gets European Approval of Hympavzi Hemophilia Drug
Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen ...
Pharmabiz2d
Pfizer’s Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors
Pfizer’s Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors: New York Thursday, November 21, 2024, 0 ...
FierceBiotech11d
Centessa drops phase 2 hemophilia B drug in wake of Pfizer’s Hympavzi approval
Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...